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Hantaviruses are assigned to categoriesAandCon theNational Institute ofAllergy and InfectiousDiseases
(NIAID) Priority Pathogens list and to category C on the Centers for Disease Control and Prevention (CDC)
Emergency Preparedness and Response list of boterrorism agents/diseases. These rodent-borne viruses
are members of the family Bunyaviridae and are transmitted to humans in aerosols of rodent excreta.
There are more than 20 recognized hantaviruses, some of which are associated with one of two serious
human diseases: hemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome
(HPS). Becauseof theglobaldistributionofhantaviruses, thehistorical associationofHFRS-causingviruses
with military operations and the recent emergence of the HPS-causing viruses, efforts are continuing to
develop safe and effective hantavirus vaccines. This review addresses the significance of hantaviruses as
they relate to biodefense and provides information about conventional and molecular vaccines for HFRS
that have advanced to clinical studies.
Published by Elsevier Ltd.
1. Introduction
1.1. Hemorrhagic fever with renal syndrome
Hantaviruses and diseases that they cause have a long associ-
ation with war and military operations. It is suspected that the
7000 cases of “war nephritis” reported among British soldiers sta-
tioned in Flanders during World War I were caused by hantavirus
infections. In the early 1930s, Russian troops encountered a dis-
ease with nephritis, bleeding, and shock along the Amur River,
which forms theborder between far-easternRussia andManchuria.
Around the same time, the Japanese Army suffered more than
12,000 cases of a similar disease when they invaded Manchuria
(reviewed in [1]). Both Japanese and Chinese conducted experi-
ments in humans, mostly prisoners of war, and established that
they could reproduce the disease by injecting urine or blood from
infected humans or field mice, and that they could serially pas-
sage the disease in humans [1]. During the Korean War, a disease
characterized by shock and renal failure, known as Korean hemor-
rhagic fever (KHF) or epidemic hemorrhagic fever, appeared among
several thousand United Nations personnel, leading to a quarter
century of efforts to identify the causative agent. In the early 1980s,
the etiologic agent of KHF, Hantaan virus (HTNV) was finally iso-
lated from the lungs of Korean field mice and propagated in cell
culture [2,3]. Several diseases that were clinically similar to KHF
were soon shown to be caused by viruses related to HTNV and
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the term HFRS was adopted by the World Health Organization in
1983 to consolidate the nomenclature for the diseases [4]. The anti-
genic and molecular characterization of these viruses led to the
establishment of the Hantavirus genus in the family Bunyaviridae
in 1989 [5–7]. Today, four hantaviruses are known to cause HFRS:
HTNV, Seoul virus (SEOV), Puumala virus (PUUV) andDobrava virus
(DOBV).
Not only does HFRS have a historical association with war, it is
also a significant public health threat. Thousands of cases of HFRS
occur in China each year, with a peak of ∼116,000 cases and ∼2500
deaths recorded in 1986 [8,9]. The Chinese cases are caused by
infections with either HTNV or SEOV. HFRS caused by PUUV or
DOBV is also highly endemic in Europe, Scandinavia, and Russia,
with the greatest incidences observed in Finland (∼25,000 cases
from1979 to2006)andwesternRussia (∼89,000cases from1996 to
2006) [10]. Epidemics have also occurred; for example, The Repub-
lic of Bashkortostan reported more than 10,000 cases of HFRS, with
an incidence rate of 287 per 100,000 in 1997 [11].
HFRS presents with sudden fever, chills, nausea, headache, and
backache. Early symptoms of severe HFRS often also include facial
flushing, conjunctivitis, and petechial rash. Themost serious aspect
of the disease is vascular leakage, leading to low blood pressure,
acute shock, and renal failure, which can cause fluid overload. Mor-
tality ranges have been estimated from less than 1% to 15%, with
HTNV and DOBV infections causing more fatalities than SEOV or
PUUV infections. PUUV rarely causes shock, although renal prob-
lems are common, and about 5% of patients require dialysis [12].
There is evidence that the severity of HFRS correlates with a par-
ticular subset of human major histocompatibility complex (HLA),
markers, suggesting a genetic susceptibility to disease [13,14].
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Table 1
Hantavirus Vaccines Tested in Humans.
Hantavirusa Vaccine substrate or vector Inactivation method or expression products Vaccination schedule (wks) Country where tested References
HTNV Suckling mouse brain Formalin 0, 4, 52 Korea 37, 38
SEOV Golden hamster kidney cells Formalin 0, 2, 4, 52 China 34b
HTNV Mongolian gerbil kidney cells -propiolactone 0, 1, 2, 52 China 34b
HTNV Suckling mouse brain Formalin 0, 2, 4, 52 China 34b
SEOV/HTNV Golden hamster kidney cells Formalin 0, 2, 4 China 40
HTNV Vaccinia virus GN, GC, N 0, 2 U.S./Korea 42
HTNV/PUUV Plasmid pWRG7077 GN, GC 0, 4, 8 U.S. (in progress) Unpublished
a Hantaan virus (HTNV); Seoul virus (SEOV); Puumala virus (PUUV).
b Review includes Chinese literature references.
Complete recovery fromany of these hantavirus infections can take
weeks or months.
1.2. Hantavirus (cardio) pulmonary syndrome (HPS)
The existence of hantaviruses in the US was known since 1983,
when Prospect Hill virus (PHV) was isolated from a meadow vole
in Frederick, MD [15,16]. Many attempts to show pathogenicity of
this virus failed, and for more than a decade it was believed that
New World hantaviruses were not pathogenic. In addition to PHV,
rat-borne SEOV was found in several sites in the US [17], but was
not associated with typical HFRS. SEOV, which is not native to the
New World, was introduced when rats were brought over on ships
from the Old World. The first appearance of an acute hantavirus-
associated disease in the New World occurred in 1993 when a
cluster of cases of adult respiratory distress were observed in the
southwestern US. Within days of obtaining clinical specimens, the
disease was shown to be caused by a previously unrecognized han-
tavirus, now known as Sin Nombre virus (SNV), that was carried by
deermice [18]. After the discovery of SNV, several other pathogenic
and presumably nonpathogenic hantaviruses were identified in
various rodent species throughout the New World. None of the
North American hantaviruses have been shown to be transmit-
ted person-to-person; however, there is evidence that the South
American virus, Andes virus, can occasionally be contagious among
humans [19,20]. The disease caused by these hantaviruses, HPS, is
sometimes referred to as hantavirus cardiopulmonary syndrome to
recognize the cardiogenic shock often associated with the disease
[21,22].
Early symptoms of HPS include fever, general malaise and mus-
cle aches. In addition, nausea, vomiting, headaches, abdominal pain
and other symptoms can occur. After about 4–10 days, patients can
develop a pulmonary capillary leak syndrome leading to respira-
tory distress symptoms characterized by coughing and shortness
of breath as the lungs fill with fluid. Like HFRS, HPS-severity might
correlate with a genetic predisposition [23]. More than 2500 cases
of HPS have occurred in the New World since 1993 with mortality
rates ranging from 30% to 40%.
2. Vaccines for hantaviral diseases
2.1. Virus structure and immune responses
Hantaviruses have three segments of negative-sense single-
strand RNA designated as large (L), medium (M) and small (S),
which encode the viral RNA-dependent RNA polymerase (L), enve-
lope glycoproteins (GN and GC), and nucleocapsid protein (N),
respectively (reviewed in [24]). Protective immunity is generally
thought to correlate with neutralizing antibodies to GN and GC,
and passive transfer of sera containing neutralizing antibodies can
provide protection against infection in animals [25–27]. Although
antibody-mediated protection is probably key, cytotoxic T cells
have been identified in samples from infected humans, and may
play a role in both protective immunity and pathogenesis of the
diseases [23,28,29].
Elucidating the exact nature of protective immune responses to
hantaviral infections has been hindered by the lack of good ani-
mal models of disease. None of the Old World hantaviruses cause
frank illness or death in any animal model, although mild disease,
similar to that sometimes observed in humans, has been reported
for PUUV infections of nonhuman primates [30,31]. Similarly, all of
the North American and most of the South American hantaviruses
cause no discernible disease in animals. An exception is Andes virus
(ANDV), which causes a lethal disease in hamsters that is very sim-
ilar to human HPS [32]. To date, because HPS is a relatively rare
disease, most vaccine efforts have been directed at HFRS; thus pro-
tection is usually measured by the ability to protect from infection.
This review is focused only on vaccines that have been tested in
humans. Other reviews have appeared recently that contain addi-
tional sources of information on studies in animals [33–35].
2.2. Conventional vaccine approaches
Both rodent brain and cell culture-derived inactivated vac-
cines for HFRS have been developed and tested in humans in
Asia (Table 1), although none has been approved for use in the
US. Rodent brain-derived vaccines are not common in western
countries, in part because of concerns about the possibility of
autoimmuneencephalitis due to thepresenceof evenminutequan-
tities of myelin basic protein contaminants [36]. A commercial
suckling mouse brain-derived vaccine, Hantavax®, has been mar-
keted in Korea for more than 10 years, with no reported safety
issues. This formalin-inactivated suckling mouse brain prepara-
tion is formulated with aluminum hydroxide adjuvant and given
as a series of two vaccinations 1 month apart with a booster 12
months later. The vaccinewas reported to elicit antibody responses
detectable by ELISA in most vaccinees, but neutralizing antibod-
ies were detected in only about half of the recipients [37,38]. As
yet, field trials with Hantavax® have not been conducted, and
a case–control study did not have sufficient statistical power to
demonstrate efficacy [39].
In China, HTNV- and SEOV-inactivated vaccines have been pro-
duced in Mongolian gerbil kidney or golden hamster kidney cell
cultures, respectively. Comparing these vaccines and a suckling
mouse brain-derived HTNV vaccine in more than 100,000 humans
demonstrated that the SEOV vaccine elicited neutralizing antibody
responses in about 80% of recipients receiving three doses, while
three doses of either of the two HTNV vaccines elicited neutraliz-
ing antibodies in only about half of the vaccinees (reviewed in [34]).
An inactivated, bivalent vaccine was also developed and tested in
China, which consisted of HTNV isolated from a HFRS case, and
SEOV isolated from a rat. The viruses were propagated in primary
hamster kidney cells, inactivated with formaldehyde, purified by
column chromatography, and formulated with aluminum hydrox-
ide adjuvant. Two or three vaccinations at 2-week intervals were
given tomore than500people in southernChinaandmore than600
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people in northern China. Not all vaccineeswere examined for anti-
body responses, but of those that were, 93% (84/90) or 92% (83/90)
developed neutralizing antibodies to HTNV or SEOV, respectively
after three doses. The rates were only slightly lower for those that
were given two doses [40].
2.3. Molecular vaccines
Molecular approaches to vaccines for HFRS and HPS circum-
vent some of the problems associated with cell culture or rodent
brain-derived vaccines. To date, only two molecular vaccines for
HFRS have been tested in humans (Table 1), the first of which was
a recombinant vaccinia virus (VACV)-vectored vaccine expressing
the M and the S segments of HTNV [41]. A Phase I dose-escalation
studywas conducted in 16 volunteers divided into four groups [42].
One group of VACV-immune and one group of VACV-naïve indi-
viduals received about 3×105 plaque-forming units (PFU) of the
vaccine by subcutaneous (s.c.) inoculation. The other two groups
were VACV-naïve and received about 3×106 or 3×107 PFU of vac-
cine. No adverse events were observed in any of the groups, but
only those receiving the highest dose developed neutralizing anti-
bodies to HTNV, with geometric mean titers (GMT) peaking 14
days after vaccination and dropping to baseline levels at 42 days. A
booster vaccination, given 1-year later resulted in a rapid anemnes-
tic response in the group of volunteers who had originally received
the highest dose of vaccine. Those in the group originally receiving
the second highest does also developed neutralizing antibodies,
but the kinetics of the response were more similar to a primary
response than to an anemnestic response [42].
A second study in 12 volunteers, showed that two s.c. vacci-
nations with the high dose elicited neutralizing antibodies in all
volunteers, while only two of six developed neutralizing antibod-
ies after one vaccination [42]. A final Phase 1 clinical study was
conducted to compare s.c. inoculation to the more standard means
of vaccinia virus vaccination, scarification. Groups of six VACV-
immune or six VACV-naïve volunteers were vaccinated twice by
scarification with ∼105 PFU of the vaccine. An additional group of
six VACV-immune volunteers received two s.c. inoculations with
∼107 PFU of vaccine. All of the scarified VACV-naïve volunteers,
but none of the VACV-immune volunteers developed neutralizing
antibodies to HTNV, while four of six VACV-immune individuals
vaccinated by the s.c. route developed neutralizing antibodies to
HTNV [42].
Because the VACV-vectored vaccine also contained the N pro-
tein ofHTNV, andbecauseprotective immunityhas beenassociated
with responses to N in animals [25], lymphocyte proliferation
responses were measured for all recipients in the Phase 1 stud-
ies. In general, the proliferative response paralleled the antibody
responses. Of interest, lymphocyte proliferation responses to the
HPS-causing SNV aswell as toHTNV could also be detected inmany
of the samples, demonstrating a possiblemeans of cross-protective
immunity for HFRS and HPS.
A Phase 2, double blinded, placebo controlled study was next
conducted to evaluate two s.c. vaccinations of the VACV-vaccine
given at 6-week intervals. Neutralizing antibodies to HTNV were
observed in 72% of vaccinia virus-naive volunteers, but only 26%
of the vaccinia virus-immune volunteers developed neutralizing
antibody responses to HTNV. Consequently, this vaccine has not
been pursued.
The other molecular hantavirus vaccine approach that has
advanced to clinical studies is plasmid DNA delivered by gene gun.
BecauseDNAvaccineshavenoprotein component, preexisting vec-
tor immunity is not a problem. Another advantage of the DNA
vaccine platform is the ability to readily construct combination
vaccines, which is important for HFRS in that it has been shown
that there is cross-protection among HTNV, SEOV, and DOBV but
not PUUV in animals [43,44]. Consequently, to protect from all
HFRS-causing hantaviruses, it will be necessary to include both a
HTNV (or SEOVorDOBV) and a PUUV component. Toward this goal,
DNA vaccines for HTNV and PUUV have been developed and tested
in animals. The HTNV DNA vaccine expresses slightly modified M
segments of HTNV or a human isolate of PUUV from Russia [45,46].
A Phase 1 clinical study of these vaccines is in progress and
includes three groups of nine volunteers that are receiving three
doses of 8g of DNA vaccines for HTNV, PUUV, or HTNV+PUUV at
4-week intervals. At every dosing, each volunteer is being vacci-
nated at four separate sites on the inner, upper arm, with those in
the single group receiving four administrations of HTNV or PUUV
and those in the combination group receiving two each of theHTNV
and PUUV vaccines. The vaccines are being delivered by hand-held
disposable devices that propel DNA coated gold beads into the epi-
dermis of the volunteers (PowderMed Vaccines). This study should
provide valuable informationboth about thepotential of theseDNA
vaccines, aswell as about theuse of thedisposable genegundevices
for eliciting safe and immunogenic responses.
3. Concluding remarks
Hantaviruses are distributed throughout the world and cause
serious human diseases, which pose particular threats to military
personnel who might come in contact with rodents in field oper-
ations. Both conventional and molecular vaccines for HFRS have
shown promise in clinical studies. In Asia, the focus on vaccine
development for HFRS continues to be inactivated vaccines, and
it is likely that if these vaccines can be distributed widely enough,
a continued reduction in HFRS should continue. There have been
no similar efforts for HFRS vaccine development for Europe, in
part because PUUV is so difficult to propagate in cell culture, and
rodent brain-derived vaccines are not considered desirable. More-
over, because DOBV and PUUV can both cause HFRS in the same
region, and because there is little or no cross-protective immu-
nity to these hantaviruses, a comprehensive vaccine for European
HFRS will require two components. A molecular vaccine, there-
fore, appears to be a more feasible solution for HFRS prevention
in Europe.
To date, vaccines for HPS have not been tested in humans.
Although HPS is among the most pathogenic of human viral infec-
tions, it is a relatively rare disease. Consequently, funding for HPS
vaccines is not a high priority for most countries. It is possible that
as more cases are recognized, particularly in South America, vac-
cine efforts may receive better support. If so, molecular vaccines
would again seem to be the best approach, because producing large
quantities of anHPSvirus for inactivationwould require specialized
high-containment facilities. Finally, although vaccines are gener-
ally the best means to prevent any disease, it is possible to reduce
HFRS and HPS infections through rodent control and through exer-
cise of precautions when cleaning rodent infested areas.
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